Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Common Equity: 2019-2024

Historic Common Equity for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $134.0 million.

  • Silence Therapeutics' Common Equity fell 41.54% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year decrease of 41.54%. This contributed to the annual value of $134.0 million for FY2024, which is 509.39% up from last year.
  • As of FY2024, Silence Therapeutics' Common Equity stood at $134.0 million, which was up 509.39% from $22.0 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Common Equity peaked at $134.0 million during FY2024, and registered a low of $11.6 million during FY2020.
  • For the 3-year period, Silence Therapeutics' Common Equity averaged around $61.1 million, with its median value being $27.2 million (2022).
  • In the last 5 years, Silence Therapeutics' Common Equity slumped by 56.43% in 2020 and then soared by 509.39% in 2024.
  • Silence Therapeutics' Common Equity (Yearly) stood at $11.6 million in 2020, then rose by 0.84% to $11.7 million in 2021, then spiked by 132.05% to $27.2 million in 2022, then decreased by 19.21% to $22.0 million in 2023, then soared by 509.39% to $134.0 million in 2024.